Deprescribing and Optimal Selection of Proton Pump Inhibitors (Contributions of the 26th United Russian Gastroenterology Week)

Aim. Presentation of the Forum “Deprescribing and optimal selection of proton pump inhibitors” held in Moscow on 29 September 2020 during the 26th United Russian Gastroenterology Week.
Key points. The Forum was aimed at discussing issues associated with improving the proton pump inhibitor (PPIs) therapy in treatment and prevention of acid-related diseases and upper gastrointestinal tract (GIT) disorders induced by non-steroidal anti-inflammatory drugs (NSAIDs) and antiplatelet medications. Deprescribing is considered to be an effective strategy of a motivated reduction of the PPI dosage, duration of therapy and the patient’s transfer from a regular to on-demand intake regimen. The choice of PPI may condition an optimal therapy for acid-related diseases.
Conclusion. PPIs prevail in therapies for acid-related diseases and NSAID-induced upper GIT lesions. PPI deprescribing should be a strategy of choice if medically indicated. A non-enzymatic metabolism, high acid suppression, stable antisecretory effect from day 1 of therapy and cytoprotective action justify the application of rabeprazole (Pariet®) for optimising therapies for acid-related diseases and implementing the deprescribing strategy.

1. Marelli S., Pace F. Rabeprazole for the treatment of acid-related disorders. Expert Rev Gastroent Hepatol. 2012;6(4):423–35. DOI: 10.1586/egh.12.18

2. Ivashkin V.T., Maev I.V., Trukhmanov A.S., Lapina T.L., Storonova O.A., et al. Recommendations of Russian Gastroenterological Association in diagnosis and treatment of gastroesophageal reflux desease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(4):70–97 (In Russ.). DOI: 10.22416/1382-4376-2020-30-4-70-97

3. Kuo C.W., Wang S.S., Hsu W.H., Kuo F.C., Weng B.C, Li C.J., et al. Rabeprazole can overcome the impact of CYP2C19 polymorphism on quadruple therapy. Helicobacter. 2010;15(4):265–72. DOI: 10.1111/j.15235578.2010.00761.x

4. McNicholl A.G., Linares P.M., Nyssen O.P., Calvet X., Gispert J.P. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;36(5):414–25. DOI: 10.1111/j.1365-2012.05211.x

5. Skoczylas T., Sarosiek I., Sostarich S., McElhinney C., Durham S., Sarosiek J. Significant enhancement of gastric mucin content after rabeprazole administration: its potential clinical significance in acid-related disorders. Dig Dis Sci. 2003;48(2):322–8. DOI: 10.1023/a:1021983611768

6. Guslandi M. Proton Pump Inhibitors and Mucus Secretion. Dig Dis Sci. 2010;55(1):217. DOI: 10.1007/s10620009-1028-5

7. Sarosiek I., Olyaee M., Majevski M., Sidorenko E. Roeser K., Wallner G., Sarosiek J. Significant increase of esophageal mucin secretion in patients with reflux esophagitis after healing with rabeprazole: its esophagoprotective potential. Dig Dis Sci. 2009;54:2137–42. DOI: 10.1007/s10620-008-0589-z

8. Weijenborg P.W., Cremonini F., Smout A.J., Bredenoord A.J. PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis. Neurogastroenterol Motil. 2012;24(8):747–57, e350. DOI: 10.1111/j.1365-2982.2012.01888.x

9. Robinson M., Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs. 2003;63(24):2739–54. DOI: 10.1111/j.13652036.2004.02160.x

10. Besancon M., Simon A., Sachs G., Shin J.M. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J. Biol Chem. 1997;272:22438–46. DOI: 10.1074/jbc.272.36.22438

11. Kromer W. Relative efficacies of gastric proton-pump inhibitors on a milligram basis: desired and undesired SH reactions. Impact of chirality. Scand J Gastroenterol Suppl. 2001;(234):3–9. DOI: 10.1080/003655201753265389

12. Kromer W., Kruger U., Huber R., Hartmann M., Steinijans V.W. Differences in pH dependent activation rates of substituted benzimidazoles and control over acid secretion and onset of symptom biological in vitro correlates. Pharmacology. 1998;56:57–70. DOI: 10.1159/000028183

13. Pantoflickova D., Dorta G., Ravic M., Jornod P., Blum A.L. Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther. 2003;17:1507–14. DOI: 10.1046/j.13652036.2003.01496.x

14. Horn J. Review article: understanding the pharmacodynamic and pharmacokinetic differences between proton pump inhibitors — focus on pKa and metabolism. Alimentary Pharmacology & Therapeutics Symposium Series. 2006;2:340–50. DOI: 10.1111/j.1746-6342.2006.00065.x

15. Dekkers C.P., Beker J.A., Thjodleifsson B., Gabryelewicz A., Bell N.E., Humphries T.J. Double-blind placebo controlled comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group. Aliment Pharmacol Ther. 1999;13(1):49–57. DOI: 10.1046/j.1365-2036.1999.00438.x

16. Kastelein F., Spander M.C., Steyerberg E.W., Biermann K., Valkhoff V.E., Kuipers E.J., Bruno M.J. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett’s esophagus. Clin Gastroenterol Hepatol. 2013;11(4):382–8. DOI: 10.1016/j.cgh.2012.11.014

17. Scally B., Emberson J.R., Spata E., Reith C., Davies K., Halls H., et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomized trials. Lancet Gastroenterol Hepatol. 2018;3(4):231–41. DOI: 10.1016/S2468-1253(18)30037-2

18. Jaworski T., Sarosiek I., Sostarich S., Roeser K., Connor M., Brotze S., et al. Restorative Impact of Rabeprazole on Gastric Mucus and Mucin Production Impairment During Naproxen Administration Its Potential Clinical Significance. Dig Dis Sci. 2005;50(2):357–65. DOI: 10.1007/s10620-005-1611-3

19. Shay H., Sun D.C.H. Etiology and pathology of gastric and duodenal ulcer. In: Bockus H.L. Gastroenterology, Philadelphia-London: Saunders Elsevier, 1968:420–65.

20. Al-Haddad S., Chang A.C., De Hertogh G., Grin A., Langer R., Sagaert X. et al. Infection and esophageal cancer. Ann NY Acad Sci. 2014;1325:187–6. DOI: 10.1111/nyas.12530

21. Snider E.K., Freedberg D.E., Abrams J.A. Potential role of the microbiome in Barrett’s esophagus and esophageal adenocarcinoma. Dig Dis Sci. 2016;61(8):2217–25. DOI: 10.1007/s10620-016-4155-9

22. Abreu M.T., Peek R.M. Gastrointestinal Malignancy and the Microbiome. Gastroenterology. 2014;146(6):1534–46. e3. DOI: 10.1053/j.gastro.2014.01.001

23. Vesper B.J., Jawdi A., Altman K.W., Haines G.K.III, Tao L., Radosevich J.A. The effect of proton pump inhibitors on the human microbiota. Curr Drug Metabol. 2009;10:84–9. DOI: 10.2174/138920

24. Rumyantseva D.Y., Trukhmanov A.S., Kudryavtseva A.V., Ivashkin V.T. Effect of antisecretory treatment on gastrointestinal microbiota. Rus J Gastroenterol Hepatol Coloproctol. 2018;28(1):78–88 (In Russ.). DOI: 10.22416/1382-43762018-28-1-78-88

25. Thompson W., Farrell B. Deprescribing: what is it and what does the evidence tell us? Can J Hosp Pharm. 2013;66(3):201–2. DOI: 10.4212/cjhp.v66i3.1261

26. Farrell B., Pottie K., Thompson W., Boghossian T., Pizzola L., Rashid F.J., et al. Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline. Can Fam Phys. 2017;63(5):354–64.

27. Boghossian T.A., Rashid F.J., Thompson W., Welch V., Moayyeddi P., Rojas-Fernandez C., et al. Deprescribing versus continuation of chronic proton pump inhibitor use in adults. Cochrane Database Syst Rev. 2017;3(3):CD011969. DOI: 10.1002/14651858.CD011969

28. Simanenkov V.I., Tikhonov S.V., Lischuk N.B. Treatment compliance at initial and maintenance therapy at gastroesophageal reflux disease. Rus J Gastroenterol Hepatol Coloproctolo. 2017;27(1):29–34 (In Russ.). DOI: 10.22416/1382-4376-2017-27-1-29-34

29. Helgadottir H., Bjornsson E.S. Problems associated with deprescribing of proton pump inhibitors. Int J Mol Sci. 2019;20(21):5469. DOI: 10.3390/ijms20215469

30. Kinoshita Y., Ishimura N., Ishihara S. Advantages and disadvantages of long-term proton pump inhibitor use. J Neurogastroenterol Motil. 2018;24(2):182–96. DOI: 10.5056/jnm18001

31. Sibbing D., Morath T., Stegherr J., Braun S., Vogt W., Hadamitzky M., et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost. 2009;101:714–9.

32. Sharara A., Malli A., El-Halabi M., Mansour N., Ghaith O., Harb R., et al. The Effect of CYP2C19 genetic polymorphisms and the concomitant use of rabeprazole or esomeprazole on the anti-platelet action of clopidogrel. Amer J Gastroenterol. 2011;106 (Suppl):S37–8.

33. Ahn J.H., Park Y., Bae J.S., Jang J.Y., Kim K.H., et al. Influence of rabeprazole and famotidine on pharmacodynamic profile of dual antiplatelet therapy in clopidogrel-sensitive patients: The randomized, prospective, PROTECT trial. Platelets. 2020;31(3):329–36. DOI: 10.1080/09537104.2019.1609667

34. Lodato F., Azzaroli F., Di Girolamo M., Feletti V., Cecinato P., Lisotti A.F., et al. Proton pump inhibitors in cirrhosis: Tradition or evidence based practice? World J Gastroenterol. 2008;14(19):2980–5. DOI: 10.3748/wjg.14.2980

35. Caos A., Breiter J., Perdomo C., Barth J. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States. Aliment Pharmacol Ther. 2005;22(3):193–202. DOI: 10.1111/j.1365-2036.2005.02555.x

36. Vaezi N.F., Yang Y.X., Howden C.W. Complications of proton pump inhibitors. Gastroenterology. 2017;153(1):35–48. DOI: 10.1053/j.gastro.2017.04.04

37. Wang C.H., Li C.H., Hsieh R., Fan C.Y., Hsu T.C., Chang W.C., et al. Proton pump inhibitors therapy and the risk of pneumonia: a systemic review and meta-analysis of randomized controlled trials and observational studies. Expert Opin Drug Saf. 2019;18(3):163–72. DOI: 10.1080/14740338.2019.1577820

38. Batchelor R., Kumar R., Gilmartin-Thomas J.F.M., Hopper I., Kemp W., Liew D. Systemic review with meta-analysis: risk of adverse cardiovascular events with proton pump inhibitors independent of clopidogrel. Aliment Pharmacol Ther. 2018;48(8):780–96. DOI: 10.1111/apt.14955

39. Liao S., Gan L., Mei Z. Does the use of proton pump inhibitors increase the risk of hypomagnesemia? An update systematic review and meta-analysis. Medicine (Baltimore). 2019;98(13):e15011. DOI: 10.1097/MD.0000000000015011

40. McQuaid K.R., Laine L. Early heartburn relief with proton pump inhibitors: a systematic review and metaanalysis of clinical trials. Clin Gastroenterol Hepatol. 2005;3(6):553–63. DOI: 10.1016/S1542-3565(05)00023-6

41. Tang H.L., Li Y., Hu Y.F., Xie H.G., Zhai S.D. Effects of CYP2C19 loss-of-function variants on the eradication of

42. H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials. PLoS One. 2013;8:e62162. DOI: 10.1371/journal.pone.0062162

43. Yasuda S., Horai Y., Tomono Y., Nakai H., Yamato C., Manabe K., et al. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4’-hydroxylation status. Clin Pharmacol Ther. 1995;58(1):43–154. DOI: 10.1016/0009-9236(95)90192-2

44. Tanaka M., Ohkubo T., Otani K., Suzuki A., Kaneko S., Sugawara K., et al. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4’-hydroxylation phenotype and genotype. Clin Pharmacol Ther. 1997;62:619–28. DOI: 10.1016/S00099236(97)90081-3

45. Sohn D-R., Kwon J.T., Kim H. K., Ishizaki T. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4’-hydroxylation phenotype status. Clin Pharmacol Ther. 1997;61(5):574–82. DOI: 10.1016/S0009-9236(97)90137-5

46. Hughes D., Bodger, K., Bytzer P., de Herdt D., Dubois D. Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease. Pharmacoeconomics. 2005;23(10):1031–41. DOI: 10.2165/00019053-200523100-00006

47. Watanabe T., Higuchi K., Tominaga K., Fujiwara Y., Arakawa T. Cytoprotective effect of rabeprazole against ethanol-induced gastric mucosal damage: possible involvement of nitric oxide: possible involvement of nitric oxide. Drug Exptl Clin Res. 2000;26(2):41–45. PMID: 10894554

48. Okazaki M., Shimizu I., Ishikawa M., Fujiwara S., Yamamoto H., Shiraishi T., et al. Gastric mucosal levels of prostaglandins and leukotrienes in patients with gastric ulcer after treatment with rabeprazole in comparison to treatment with ranitidine. J Med Invest. 2007;54(1–2):83–90. DOI: 10.2152/jmi.54.83

49. Ivashkin V.T., Maev I.V., Ivashkin K.V., Korochanskaya N.V., Lopina O.D., Lapina T.L. Trukhmanov A.S., Lapina T.L., et al. The role of protective factors disorders of acid-related diseases pathogenesis. Rus J Gastroenterol Hepatol Coloproctol. 2016;26(3):115–6 (In Russ.).